← Back to Home

Oral Ulcerative Colitis Drug OD-001 Shows Phase 2 Efficacy Signal, Will Advance to Randomized Controlled Testing

Odyssey reported full 12-week induction treatment results, with 27% of patients in the higher-dose group achieving clinical remission. However, this open-label study had no concurrent placebo group, leaving the next stage of trials to determine how much additional benefit the drug provides.

By SURL BioNews

The test for a new ulcerative colitis drug is not just whether disease activity scores decline, but how much of the improvement comes from the drug itself. On October 20, Odyssey Therapeutics reported full induction-period results from an early Phase 2 trial of its oral drug candidate OD-001. The study met its primary endpoint and provided a basis for further development in controlled trials, but these results cannot yet establish efficacy.

The study enrolled patients with moderate to severe disease and used an open-label, dose-finding design. Among 56 patients evaluable for efficacy, the modified Mayo disease activity score fell by an average of 2.4 points from baseline after 12 weeks of treatment. The clinical remission rate was 27% among the 41 patients receiving 20 milligrams twice daily and 20% among the 15 patients receiving 10 milligrams twice daily. RTTNews also reported the primary endpoint and remission results for the higher-dose group.

These figures need to be interpreted alongside the study design. The trial had no concurrent placebo group, and both patients and the study team knew which treatment was being given, so the effects of natural fluctuations in disease activity and other factors cannot be ruled out. Both dose groups were small, and the difference in remission rates alone is insufficient to demonstrate a relationship between dose and efficacy. The company also cautioned that the database had not yet been locked and the data could still change.

OD-001 targets the scaffolding function of RIPK2 for inhibition. According to the company, exploratory analyses of paired intestinal biopsies showed reductions in some RIPK2-related and downstream inflammatory gene signals after treatment, consistent with the direction of clinical improvement. This supports the proposed mechanism of action, but changes in gene expression cannot replace controlled trials or directly demonstrate that the drug is superior to existing therapies.

On safety, the company reported no serious adverse events, serious infections, discontinuations due to treatment-related adverse reactions, or treatment-emergent liver function abnormalities during the 12-week induction period. Two cases of fever and one case of headache in the 20-milligram group were considered drug-related. This is a preliminary signal of short-term tolerability and is not yet sufficient to characterize the risks of long-term use.

Background

Oral drug development for ulcerative colitis is exploring different approaches. For example, Cosmo is seeking efficacy with a locally administered rifamycin formulation, while OD-001 targets a RIPK2-related mechanism. Enrollment criteria, treatment durations, and analysis populations vary across studies, so remission rates cannot be used to directly rank treatments. The shared hurdle is whether early signals can be reproduced in more rigorous, longer-term studies.

Odyssey next plans a double-blind, randomized, placebo-controlled late Phase 2 monotherapy trial, as well as an early Phase 2 combination treatment trial comparing “OD-001 plus vedolizumab” with “vedolizumab plus placebo.” The company expects to report primary induction-period results from both studies in the second half of 2027. Those results should more clearly distinguish the benefits of OD-001 alone and whether adding it to an existing therapy can provide additional improvement.

References

  1. Odyssey Therapeutics / SEC
  2. RTTNews